Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Performance characteristics of plasma amyloid-beta 40 and 42 assays.

Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F.

J Alzheimers Dis. 2009;16(2):277-85. doi: 10.3233/JAD-2009-0948.

2.

Cardiovascular risk and memory in non-demented elderly women.

Wang S, Jacobs D, Andrews H, Tsai WY, Luo X, Bergmann C, Sano M.

Neurobiol Aging. 2010 Jul;31(7):1250-3. doi: 10.1016/j.neurobiolaging.2008.08.007. Epub 2008 Sep 21.

3.

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.

Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7. doi: 10.1073/pnas.0805902105. Epub 2008 Sep 8.

4.

Amyloid-associated depression: a prodromal depression of Alzheimer disease?

Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ.

Arch Gen Psychiatry. 2008 May;65(5):542-50. doi: 10.1001/archpsyc.65.5.542.

5.

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.

Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST.

Neurology. 2008 May 6;70(19):1664-71. doi: 10.1212/01.wnl.0000306696.82017.66. Epub 2008 Apr 9.

6.

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L.

Arch Neurol. 2008 Feb;65(2):256-63. doi: 10.1001/archneurol.2007.57.

PMID:
18268197
7.

Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families.

Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR.

Neurology. 2008 Feb 19;70(8):596-606. Epub 2007 Oct 3.

PMID:
17914065
8.

Neuropsychological measures in normal individuals that predict subsequent cognitive decline.

Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M.

Arch Neurol. 2007 Jun;64(6):862-71.

PMID:
17562935
9.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
10.

A randomized trial of vitamin E supplementation and cognitive function in women.

Kang JH, Cook N, Manson J, Buring JE, Grodstein F.

Arch Intern Med. 2006 Dec 11-25;166(22):2462-8.

PMID:
17159011
11.

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM.

Lancet Neurol. 2006 Aug;5(8):655-60.

PMID:
16857570
12.

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.

Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD.

Neurology. 2003 Nov 11;61(9):1185-90.

PMID:
14610118
13.

Looking backward to move forward: early detection of neurodegenerative disorders.

DeKosky ST, Marek K.

Science. 2003 Oct 31;302(5646):830-4. Review.

PMID:
14593169
14.

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC.

Arch Neurol. 2003 Jul;60(7):958-64.

PMID:
12873852
15.

Silent brain infarcts and the risk of dementia and cognitive decline.

Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM.

N Engl J Med. 2003 Mar 27;348(13):1215-22.

16.

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Hardy J, Selkoe DJ.

Science. 2002 Jul 19;297(5580):353-6. Review. Erratum in: Science 2002 Sep 27;297(5590):2209.

PMID:
12130773
17.

The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period.

Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, Berry-Kravis E, Bach J, Fox JH, Evans DA, Bennett DA.

Arch Neurol. 2002 Jul;59(7):1154-60.

PMID:
12117364
18.

Demonstrating the case that AD is a vascular disease: epidemiologic evidence.

Launer LJ.

Ageing Res Rev. 2002 Feb;1(1):61-77. Review.

PMID:
12039449
19.

Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study.

Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M.

Arch Gen Psychiatry. 2001 Sep;58(9):853-8.

PMID:
11545668

Supplemental Content

Support Center